Table 2.
Interleukin 17 levels in pleural effusion of lung cancer patients a
| Clinical variables | Patients ( n ) | IL-17 (pg/ml) Mean ± SD | P -value |
|---|---|---|---|
| Age (years) |
|
|
0.343 |
| ≥60 |
38 |
27.08 ± 4.87 |
|
| <60 |
40 |
19.92 ± 5.28 |
|
| Gender |
|
|
0.259 |
| Male |
36 |
21.23 ± 5.30 |
|
| Female |
42 |
19.87 ± 5.23 |
|
| Histologic type |
|
|
0.491 |
| Adenocarcinoma |
67 |
20.33 ± 6.12 |
|
| Nonadenocarcinoma |
11 |
21.52 ± 5.05 |
|
| ECOG PS |
|
|
0.256 |
| 0 or 1 |
50 |
19.99 ± 5.37 |
|
| 2 to 4 |
28 |
21.41 ± 5.21 |
|
| Cytologic examination |
|
|
0.912 |
| Positive |
60 |
20.46 ± 5.18 |
|
| Negative |
18 |
20.62 ± 6.12 |
|
| Stage |
|
|
0.706 |
| M1a |
54 |
20.34 ± 4.58 |
|
| M1b |
24 |
20.83 ± 6.01 |
|
| Location |
|
|
0.751 |
| Right |
50 |
20.34 ± 5.36 |
|
| Left | 28 | 20.15 ± 4.97 |
aECOG PS, Eastern Cooperative Oncology Group performance status; IL-17, Interleukin 17.